FDA approves Roche's Vabysmo

FDA has approved Roche's Vabysmo, a drug for the treatment of vision loss. Vabysmo is designed to treat neovascular NVMD and DME by neutralizing angiopoietin-2. A course of treatment for nVMD and DMO is given four times a month. The drug will go on sale in the U.S. in the coming weeks. The European Medicines Agency is also considering an application to register Vabysmo.